ArticleCureus2025
Interleukin-17/β-Defensin-2 Expression Before and After Periodontal Therapy in a Patient With Periodontitis/Autoimmunity.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Periodontitis is a chronic inflammatory disease that affects the supporting tissues of the periodontium. Comorbidity in patients with periodontitis with rheumatoid arthritis and psoriasis has been documented. In immunopathogenesis, it has been described that interleukin 17 participates in periodontitis and autoimmune diseases. In this regard, interleukin 17 induces the expression of β-defensin-2, an antimicrobial peptide with a proinflammatory effect. Currently, it is not known how periodontal therapy impacts the production of interleukin 17 and β-defensin-2. This is the first case report exploring the modification of interleukin 17/β-defensin-2 in a patient with periodontitis or autoimmunity, showing the importance and effect of non-surgical therapy on modifications of the immune response at the molecular level. The aim of this work is to evaluate the clinical improvement and the levels of interleukin 17/β-defensin-2 in saliva before and after periodontal treatment in a patient with periodontitis, rheumatoid arthritis, and psoriasis. We present the case of a 51-year-old male patient with a history of psoriasis and rheumatoid arthritis. On periodontal examination, he presented with periodontal pockets greater than 5 mm in 19 periodontal sites, with 100% bleeding on probing, and tooth mobility grades II and III in most of the dental organ. Subgingival instrumentation and oral hygiene instructions were performed. The patient showed favorable progress, with a reduction in periodontal pocket depth, bleeding on probing, and tooth mobility. Interleukin 17 levels were higher and β-defensin-2 levels were lower post-treatment. Non-surgical treatment decreased the inflammatory activity of periodontal disease, which led to increased interleukin 17 and decreased β-defensin-2 in saliva samples. The decrease in β-defensin-2 suggests its usefulness as a marker of inflammatory activity in periodontal disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.